BR112013007123A2 - processo de fabricação para derivados depirimidina - Google Patents

processo de fabricação para derivados depirimidina

Info

Publication number
BR112013007123A2
BR112013007123A2 BR112013007123A BR112013007123A BR112013007123A2 BR 112013007123 A2 BR112013007123 A2 BR 112013007123A2 BR 112013007123 A BR112013007123 A BR 112013007123A BR 112013007123 A BR112013007123 A BR 112013007123A BR 112013007123 A2 BR112013007123 A2 BR 112013007123A2
Authority
BR
Brazil
Prior art keywords
manufacturing process
derivatives
depyrimidine
solid forms
compound
Prior art date
Application number
BR112013007123A
Other languages
English (en)
Other versions
BR112013007123B1 (pt
Inventor
Baoqing Gong
Dietmar Flubacher
Hui Liu
John Vincent Calienni
Liladhar Murlidhar Waykole
Maria Caterina Testa
Marilyn De La Cruz
Pascal Michel
Piotr H Karpinski
Prasad Koteswara Kapa
Rasmus Mose
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44773179&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013007123(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112013007123A2 publication Critical patent/BR112013007123A2/pt
Publication of BR112013007123B1 publication Critical patent/BR112013007123B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/04Esters of boric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)

Abstract

processo de fabricação para derivados de pirimidina. a invenção refere-se a processos para fabricar um composto de fórmula 5, ou um estereoisômero, tautômero ou um sal do mesmo, emq que os substituintes são como definidos na especificação. a invenção também refere-se a novos processos de fabricação para formas sólidas específicas do composto a e seus sais, a tais formas sólidas e ao uso das referidas formas sólidas para o tratamento terapêutico de animais homeotérmicos.
BR112013007123-0A 2010-10-01 2011-09-29 Forma cristalina do sal de monocloridrato de um composto a, seu uso, e composição farmacêutica BR112013007123B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38872110P 2010-10-01 2010-10-01
US61/388,721 2010-10-01
US201161494915P 2011-06-09 2011-06-09
US61/494,915 2011-06-09
PCT/US2011/053808 WO2012044727A2 (en) 2010-10-01 2011-09-29 Manufacturing process for pyrimidine derivatives

Publications (2)

Publication Number Publication Date
BR112013007123A2 true BR112013007123A2 (pt) 2016-06-14
BR112013007123B1 BR112013007123B1 (pt) 2021-11-09

Family

ID=44773179

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013007123-0A BR112013007123B1 (pt) 2010-10-01 2011-09-29 Forma cristalina do sal de monocloridrato de um composto a, seu uso, e composição farmacêutica

Country Status (31)

Country Link
US (3) US9181215B2 (pt)
EP (2) EP2621908A2 (pt)
JP (3) JP5998145B2 (pt)
KR (2) KR20180123586A (pt)
CN (3) CN104945373A (pt)
AR (1) AR083213A1 (pt)
AU (4) AU2011308856B2 (pt)
BR (1) BR112013007123B1 (pt)
CA (1) CA2813333C (pt)
CL (2) CL2013000850A1 (pt)
CO (1) CO6700837A2 (pt)
DK (1) DK3040333T3 (pt)
EC (1) ECSP13012596A (pt)
ES (1) ES2699951T3 (pt)
GT (1) GT201300080A (pt)
HK (1) HK1220686A1 (pt)
HU (1) HUE041326T2 (pt)
IL (3) IL225113A (pt)
LT (1) LT3040333T (pt)
MX (1) MX354482B (pt)
MY (1) MY160785A (pt)
NZ (1) NZ608285A (pt)
PE (1) PE20140002A1 (pt)
PH (1) PH12015501585A1 (pt)
PL (1) PL3040333T3 (pt)
PT (1) PT3040333T (pt)
RU (2) RU2576619C2 (pt)
SG (1) SG188439A1 (pt)
SI (1) SI3040333T1 (pt)
TW (1) TWI540133B (pt)
WO (1) WO2012044727A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA114178C2 (uk) 2011-07-01 2017-05-10 Новартіс Аг Комбінація, що включає інгібітор cdk4/6 і інгібітор pi3k, для лікування раку
PE20141581A1 (es) 2011-09-27 2014-11-14 Novartis Ag 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
MX360703B (es) * 2012-10-23 2018-11-14 Novartis Ag Proceso mejorado para la elaboración de 5-(2, 6-di-4-morfolinil-4-pirimidinil)-4-trifluoro-metil-piridin-2-amin a.
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
PE20151939A1 (es) 2013-03-14 2016-01-08 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
US9318944B2 (en) 2013-04-29 2016-04-19 Rockwell Automation Technologies, Inc. Methods and apparatus for active front end filter capacitor degradation detection
US9294005B2 (en) 2013-10-01 2016-03-22 Rockwell Automation Technologies, Inc. Method and apparatus for detecting AFE filter capacitor degradation
JP6139789B2 (ja) * 2013-10-16 2017-05-31 シャンハイ インリ ファーマシューティカル カンパニー リミティド 縮合複素環化合物、その調製方法、医薬組成物及びその使用
AU2015250994B2 (en) * 2014-04-22 2018-12-20 Torqur Ag Novel manufacturing process for triazine, pyrimidine and pyridine derivatives
CN105085476B (zh) * 2014-11-24 2018-03-09 苏州晶云药物科技有限公司 5‑[2,6‑二(4‑吗啉基)‑4‑嘧啶基]‑4‑(三氟甲基)‑2‑吡啶胺二盐酸盐的晶型及其制备方法
US10227324B2 (en) 2014-12-17 2019-03-12 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. 2-morpholin-4,6-disubstituted pyrimidine derivative, and preparation method and pharmaceutical use thereof
US9481665B2 (en) * 2015-03-13 2016-11-01 Yong Xu Process for preparing PI3K inhibitor buparsilib
WO2016151501A1 (en) 2015-03-25 2016-09-29 Novartis Ag Pharmaceutical combinations
CN105001151B (zh) * 2015-08-28 2017-07-14 苏州明锐医药科技有限公司 布帕尼西中间体及其制备方法
CN106543140A (zh) * 2015-09-21 2017-03-29 苏州晶云药物科技有限公司 5-[2,6-二(4-吗啉基)-4-嘧啶基]-4-(三氟甲基)-2-吡啶胺盐酸盐的晶型及其制备方法
CN108697713B (zh) * 2015-12-16 2021-10-26 基因泰克公司 用于制备三环pi3k抑制剂化合物的方法及用其治疗癌症的方法
CN106905294A (zh) * 2016-07-08 2017-06-30 苏州科睿思制药有限公司 5‑[2,6‑二(4‑吗啉基)‑4‑嘧啶基]‑4‑(三氟甲基)‑2‑吡啶胺的晶型及其制备方法
CN107793394A (zh) * 2017-08-03 2018-03-13 上海厚璞生物科技有限公司 一种生产选择性pi3k抑制剂的系列关键中间体
CN110016142B (zh) * 2019-04-30 2021-08-03 合肥工业大学 一种含嘧啶硼酸结构的硅油及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124476A (en) 1998-04-17 2000-09-26 Symyx Technologies, Inc. Catalyst ligands, catalyst compositions, catalyst metal complexes and processes for cross-coupling aromatic boron compounds with aromatic halogens or perfluoroalkylsulfonates
CN1735598A (zh) * 2002-11-11 2006-02-15 拜耳医药保健股份公司 作为ip受体拮抗剂的苯基或杂芳基氨基烷烃衍生物
MXPA05005477A (es) 2002-11-21 2005-07-25 Chiron Corp Pirimidinas 2,4,6-trisustituidas como inhibidores de fosfotidilinositol (pi) 3-cinasa y su uso en el tratamiento del cancer.
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
AU2007287428B2 (en) 2006-08-24 2011-08-11 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
CN101711241A (zh) 2007-02-06 2010-05-19 诺瓦提斯公司 Pi3-激酶抑制剂和它们的使用方法
WO2009066084A1 (en) * 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
RU2011150619A (ru) * 2009-05-15 2013-06-20 Новартис Аг Комбинация ингибитора фосфоинозитид-3-киназы и противодиабетического соединения

Also Published As

Publication number Publication date
US9452994B2 (en) 2016-09-27
CN104987321A (zh) 2015-10-21
PE20140002A1 (es) 2014-01-21
CO6700837A2 (es) 2013-06-28
PH12015501585A1 (en) 2015-09-21
BR112013007123B1 (pt) 2021-11-09
TW201215605A (en) 2012-04-16
HK1220686A1 (zh) 2017-05-12
DK3040333T3 (da) 2019-01-02
IL225113A (en) 2016-08-31
CN103140479B (zh) 2015-04-08
KR20130119928A (ko) 2013-11-01
EP3040333A1 (en) 2016-07-06
AU2015200936A1 (en) 2015-03-12
KR20180123586A (ko) 2018-11-16
MX2013003507A (es) 2013-05-20
LT3040333T (lt) 2018-12-10
PL3040333T3 (pl) 2019-03-29
JP5998145B2 (ja) 2016-09-28
ES2699951T3 (es) 2019-02-13
WO2012044727A2 (en) 2012-04-05
SG188439A1 (en) 2013-05-31
MY160785A (en) 2017-03-15
TWI540133B (zh) 2016-07-01
ECSP13012596A (es) 2013-07-31
AU2015200938A1 (en) 2015-03-12
SI3040333T1 (sl) 2019-01-31
IL233282A (en) 2016-08-31
AU2015246141B2 (en) 2016-07-07
MX354482B (es) 2018-03-07
HUE041326T2 (hu) 2019-05-28
RU2013120326A (ru) 2014-11-20
CN103140479A (zh) 2013-06-05
AR083213A1 (es) 2013-02-06
US20150232446A1 (en) 2015-08-20
CL2015001088A1 (es) 2015-07-10
GT201300080A (es) 2014-07-18
IL233282A0 (en) 2014-08-31
AU2015200938B2 (en) 2015-11-19
US20160251334A1 (en) 2016-09-01
RU2015150728A (ru) 2019-01-15
IL238046A (en) 2016-08-31
JP2013541536A (ja) 2013-11-14
CA2813333A1 (en) 2012-04-05
JP2016106091A (ja) 2016-06-16
US20130225571A1 (en) 2013-08-29
CA2813333C (en) 2019-01-15
RU2576619C2 (ru) 2016-03-10
AU2015246141A1 (en) 2015-11-12
WO2012044727A3 (en) 2012-06-07
CN104945373A (zh) 2015-09-30
NZ608285A (en) 2014-06-27
PT3040333T (pt) 2018-12-04
US9359326B2 (en) 2016-06-07
JP2016128414A (ja) 2016-07-14
EP3040333B1 (en) 2018-09-12
AU2011308856A1 (en) 2013-03-28
US9181215B2 (en) 2015-11-10
AU2011308856B2 (en) 2015-04-23
EP2621908A2 (en) 2013-08-07
CL2013000850A1 (es) 2013-09-27

Similar Documents

Publication Publication Date Title
BR112013007123A2 (pt) processo de fabricação para derivados depirimidina
BR122018070836A8 (pt) Compostos de amidas heterocíclicas moduladoras de sting, composição contendo ditos compostos e uso dos mesmos para tratar uma doença mediada por sting
BR112014013974A8 (pt) derivados de sulfonamida benzílicos como moduladores de rorc
PE20160874A1 (es) Compuestos quimicos
BR112014015259A8 (pt) composições compreendendo galatos e galamidas
BR112014010576B8 (pt) compostos inibidores de neprilisina (nep), seus usos, processo de preparação dos compostos e composição farmacêutica compreendendo os compostos
EA200901488A1 (ru) Замещенные имидазолопиридазины, как ингибиторы липидкиназы
BR112014017968A8 (pt) Compostos de beta-lactama substituídos por amidina, sua preparação e uso como agentes antibacterianos
AR087794A1 (es) Proceso para preparar {1-{1-[3-fluoro-2-(trifluorometil)isonicotinoil]-piperidin-4-il}-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo, intermediarios de dicha sintesis y proceso para prepararlos
BR112014005226A2 (pt) derivados de benzonitrila como inibidores de cinase
BR112016008468A2 (pt) Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer
CO7141410A2 (es) Compuesto heterocíclico nitrogenado
EA201200952A1 (ru) Производные пиразина и их применение для лечения неврологических нарушений
EA201200176A1 (ru) Производные оксазина и их применение для лечения неврологических нарушений
BR112014005468A2 (pt) derivados de aminopiridina para uso como moduladores de atividade quinase
BR112015018547A2 (pt) microbiocidas
MX2011009847A (es) Agentes antihelminticos y su uso.
BR112012007322A2 (pt) composto de 2-piridona usados como inibidores de neutrófilo elastase
BR112017000830A2 (pt) novas 2,5-piridinas substituídas
BR112017000821A2 (pt) novos compostos de pirimidina substituída.
BR112013029999A2 (pt) derivados de tiazol
BR112015004029A2 (pt) Processo para preparação de teneligliptina, de um composto ou de sal ou hidrato do mesmo
BR112015026055A2 (pt) novos compostos de pirimidina condensados substituídos
BR112018013033A2 (pt) compostos de indolinonas e seu uso no tratamentod de doenças fibróticas
BR112013020419A2 (pt) microbicidas derivados de pirazol

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/09/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.